Virginie Supervie1, Jacques D A Ndawinz, Sara Lodi, Dominique Costagliola. 1. aSorbonne Universités, UPMC Univ Paris 06 bINSERM, UMR_S 1136 Pierre Louis Institute of Epidemiology and Public Health, Paris, France cInstituto de Salud Carlos III, Madrid, Spain dHarvard School of Public Health, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Describing the undiagnosed HIV-infected population is essential for guiding HIV screening policy, implementing interventions, and resource planning. METHODS: We used French national HIV surveillance data and a back-calculation approach to estimate the number of undiagnosed HIV-infected individuals in France and the distribution of time since HIV infection among undiagnosed individuals. We also used data on CD4⁺ cell count decline to assess the CD4⁺ cell count distribution among undiagnosed individuals. RESULTS: We estimated that 29,000 [95% confidence interval (CI): 24,200-33,900] individuals were living with undiagnosed HIV infection at the end of 2010. Of these, 28.7% (95% CI: 27.1-30.4) were infected less than a year ago, 16.4% (95% CI: 15.0-17.8) more than 5 years ago, and 59.6% (95% CI: 59.2-59.8) were eligible for antiretroviral treatment (CD4⁺ cell count less than 500 cells/μl) according to the 2010 French guidelines. Men represented 70.0% of the undiagnosed HIV-infected individuals and had lower CD4⁺ cell counts than women. The numbers of undiagnosed infections in MSM, non-French national heterosexuals, and French national heterosexuals were similar (9200, 9300, 10,000, respectively). However, because of differences in group size, undiagnosed HIV prevalence varied significantly between these groups (2.95, 0.36, 0.03%, respectively; P less than 0.001). CONCLUSION: Our findings suggest that many undiagnosed HIV-infected individuals were eligible for treatment and, thus, lack of HIV diagnosis is a lost chance for them; many more heterosexuals than MSM will need to be tested to find those undiagnosed; and universal screening of men may be cost-effective, especially in the areas most affected by the epidemic, such as the Paris region.
BACKGROUND: Describing the undiagnosed HIV-infected population is essential for guiding HIV screening policy, implementing interventions, and resource planning. METHODS: We used French national HIV surveillance data and a back-calculation approach to estimate the number of undiagnosed HIV-infected individuals in France and the distribution of time since HIV infection among undiagnosed individuals. We also used data on CD4⁺ cell count decline to assess the CD4⁺ cell count distribution among undiagnosed individuals. RESULTS: We estimated that 29,000 [95% confidence interval (CI): 24,200-33,900] individuals were living with undiagnosed HIV infection at the end of 2010. Of these, 28.7% (95% CI: 27.1-30.4) were infected less than a year ago, 16.4% (95% CI: 15.0-17.8) more than 5 years ago, and 59.6% (95% CI: 59.2-59.8) were eligible for antiretroviral treatment (CD4⁺ cell count less than 500 cells/μl) according to the 2010 French guidelines. Men represented 70.0% of the undiagnosed HIV-infected individuals and had lower CD4⁺ cell counts than women. The numbers of undiagnosed infections in MSM, non-French national heterosexuals, and French national heterosexuals were similar (9200, 9300, 10,000, respectively). However, because of differences in group size, undiagnosed HIV prevalence varied significantly between these groups (2.95, 0.36, 0.03%, respectively; P less than 0.001). CONCLUSION: Our findings suggest that many undiagnosed HIV-infected individuals were eligible for treatment and, thus, lack of HIV diagnosis is a lost chance for them; many more heterosexuals than MSM will need to be tested to find those undiagnosed; and universal screening of men may be cost-effective, especially in the areas most affected by the epidemic, such as the Paris region.
Authors: Sara Lodi; Andrew Phillips; Giota Touloumi; Ronald Geskus; Laurence Meyer; Rodolphe Thiébaut; Nikos Pantazis; Julia Del Amo; Anne M Johnson; Abdel Babiker; Kholoud Porter Journal: Clin Infect Dis Date: 2011-10 Impact factor: 9.079
Authors: A Antinori; T Coenen; D Costagiola; N Dedes; M Ellefson; J Gatell; E Girardi; M Johnson; O Kirk; J Lundgren; A Mocroft; A D'Arminio Monforte; A Phillips; D Raben; J K Rockstroh; C Sabin; A Sönnerborg; F De Wolf Journal: HIV Med Date: 2011-01 Impact factor: 3.180
Authors: Nikos Pantazis; Charles Morrison; Pauli N Amornkul; Charlotte Lewden; Robert A Salata; Albert Minga; Tsungai Chipato; Harold Jaffe; Shabir Lakhi; Etienne Karita; Kholoud Porter; Laurence Meyer; Giota Touloumi Journal: PLoS One Date: 2012-03-06 Impact factor: 3.240
Authors: Paul J Birrell; O Noel Gill; Valerie C Delpech; Alison E Brown; Sarika Desai; Tim R Chadborn; Brian D Rice; Daniela De Angelis Journal: Lancet Infect Dis Date: 2013-02-01 Impact factor: 25.071
Authors: Richelle Harklerode; Wanjiru Waruiru; Felix Humwa; Anthony Waruru; Timothy Kellogg; Lilly Muthoni; James Macharia; Emily Zielinski-Gutierrez Journal: AIDS Care Date: 2019-04-27
Authors: Ard van Sighem; Fumiyo Nakagawa; Daniela De Angelis; Chantal Quinten; Daniela Bezemer; Eline Op de Coul; Matthias Egger; Frank de Wolf; Christophe Fraser; Andrew Phillips Journal: Epidemiology Date: 2015-09 Impact factor: 4.822